Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer

Australasian Radiology

Volumn 43, Issue 2, 1999, Pages 220-226

  Lamb, D ^a   Atkinson, C ^b   Joseph, D ^c   O'Brien, P ^d   Ackland, S ^d   Bonaventura, A ^d   Dady, P ^a   Hamilton, C ^d   Spry, N ^e   Stewart, J ^d   Denham, J ^d  

^a Wellington Hospital   (United States)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d NEWCASTLE MATER HOSPITAL   (Australia)

^e GEELONG HOSPITAL   (Australia)

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; AUSTRALIA; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; EDEMA; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NEW ZEALAND; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; SURGICAL TECHNIQUE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033013406     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1673.1999.00638.x     Document Type: Article

References (31)

1. 1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 71-85.
2. 2. Cuzick J, Stewart H, Rutqvist L et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 1994; 12: 447-53.
3. 3. Overgaard M, Hansen PS. Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N, Engt. J. Med. 1997; 337: 949-55.
4. 4. Rutqvist LE, Lax I, Pomander T, Johansson H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 1992; 22: 887-96.
5. 5. Borger JH, Keijser AH Conservative breast cancer treatment: Analysis of cosmetic results and the role of concomitant adjuvant chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1987; 13: 1173-7.
6. 6. Buzdar AU, Kau SW, Smith TL et al. The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 1993; 71: 3680-4.
7. 7. Clarke DH, Lee MG, Sarrazin D et al. Analysis of local-regional relapses in patients with early breast cancer treated with excision and radio-therapy; experience of the Institut Gustave-Roussy. Int. J. Radiat. Oncol. Biol. Phys. 1985; 11: 137-45.
8. 8. Cooper MR, Rhyne AL, Muss HB et al. A randomised comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 1981; 47: 2833-9.
9. 9. Dalton WS, Brooks RJ, Jones SE. Breast cancer adjuvant therapy trials at the Arizona Cancer Centre using adriamycin and cyclophosphamide. In: Salmon SE (ed.) Adjuvant Therapy of Cancer V. Grune & Stratton, Orlando, 1987; 263-9.
10. 10. McCormick B, Norton L, Yao TJ, Yahalom J, Petrek JA. The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. Cancer J. Sci. Am. 1996; 2: 39-45.
11. 11. Nixon A, Recht A, Neuberg D et al. The relationship between the surgery - radiotherapy interval and treatment outcome In patients treated with breast-conserving surgery and radiation therapy without systemic therapy. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30: 17-21.
12. 12. Recht A, Come S, Gelman R et al. Integration of conservative surgery, radiotherapy and chemotherapy for the treatment of early stage node-positive breast cancer: Sequencing, timing and outcome. Int. J. Radiat. Oncol. Biol. Phys. 1991; 9: 1662-7.
13. 13. Recht A, Harris JR, Come SE. Sequencing of irradiation and chemotherapy for early stage breast cancer. Oncology 1994; 8: 19-28.
14. 14. Slotman BJ, Meyer OWM, Njo KH, Karim ABMR Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer. Radiother. Oncol. 1994; 30: 206-12.
15. 15. Wallgren A, Bemier J, Gelber RD et al. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 1996; 35: 649-58.
16. 16. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N. Engl. J. Med. 1996; 334: 1356-61.
17. 17. Bonaventura A, Stewart JR Ackland S, Hamilton CS, Joseph D, Denham JW, Synchronous adjuvant radiotherapy and chemotherapy for early breast cancer (Abstract), Proc. ASCO 1990; 9: 103.
18. 18. Berry RJ. Some observations on the combined effects of X-rays and methotrexate on human tumor cells in vitro with possible relevance to their most useful combination in radiotherapy. AJR 1968; 102: 509-18.
19. 19. Byfield JE. Theoretical basis and clinical applications of 5-fluorouracil as a radiosensitizer. In: Rosenthal CJ, Rotman M (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Plenum Press, New York, 1986; 113-25.
20. 20. Christie DRH, O'Brien MY, Christie JA et al. A comparison of methods of cosmetic assessment in breast conservation treatment, Breast 1996; 5: 358-67.
21. 21. Denham JW, Hamilton CS, Christie D et al. Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer: toxicity and dose modification: A Trans-Tasman Radiation Oncology Group multi-institution study. Int. J. Radiat. Oncol. Biol. Phys. 1995; 31: 305-13.
22. 22. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 1995: 273: 542-7.
23. 23. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J. Clin. Oncol. 1990; 8: 1483-96.
24. 24. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. J. Clin. Oncol. 1990; 8: 548-55.
25. 25. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 1997; 337: 956-62.
26. 26. Doroshow JH. Doxorubicin-induced cardiac toxicity. N. Engl. J. Med. 1991; 324: 843-5.
27. 27. Dresdale A, Bonow RO, Wesley R et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Am. Cancer Soc. 1983; 52: 51-60.
28. 28. Shan K, Lunkoff AM, Young JB. Anthracycline induced cardiotoxicity. Ann. Intern. Med. 1996; 25: 47-58.
29. 29. Valagussa P, Zambetti M, Biasi S, Moliterni A. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann. Oncol. 1994; 5: 209-16.
30. 30. von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979; 91: 710-17.
31. 31. Roy JA, Piccart MJ. Adjuvant systemic therapy for breast cancer. Current opinion. Oncology 1995; 7: 517-22.